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Dexmedetomidine reduces the incidence of fentanyl-induced cough: A
double-blind, randomized, and placebo-controlled study
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Department of Anesthesia, The Second Xiangya Hospital of Central South University, Changsha, China
Abstract
Objectives. The incidence of fentanyl-induced cough (FIC) during induction of general anesthesia varies around 40% and is
undesirable. It increases intracranial, intraocular, and intra-abdominal pressures. This prospective, randomized, double-blind,
placebo-controlled study evaluated the effect of dexmedetomidine (DEX) pretreatment on the incidence and severity of FIC.
Methods. Altogether 300 patients undergoing elective surgical procedures were randomly allocated into three groups (I, II, III;
n = 100) and administered intravenously, over 10 min, 10 mL isotonic saline, DEX 0.5 mg/kg in 10 mL isotonic saline, or DEX
1 mg/kg in 10 mL isotonic saline, respectively. All groups subsequently received a fentanyl (4.0 mg/kg) intravenous push. The
incidence and severity of cough were recorded for 1 min after fentanyl administration.
Results. The incidence of FIC was 61%, 40%, and 18% in groups I, II, and III, respectively (P < 0.05 for treatment groups II
and III versus control group I). There was no signiﬁcant difference in the severity or onset time of cough, or hemodynamic
variables, among the three groups.
Conclusions. Intravenous DEX (0.5 mg/kg or 1 mg/kg) immediately before the administration of intravenous fentanyl (4.0 mg/kg)
signiﬁcantly reduced the incidence of FIC.
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Introduction
Fentanyl is commonly administered during general
anesthetic induction. Fentanyl-induced cough (FIC)
is undesirable as it increases intracranial, intraocular,
and intra-abdominal pressures (1). The incidence of
FIC varies from 18% to 65% (1–4). The mechanism
of FIC is unclear, and various drugs and techniques
are used to reduce its incidence.
Clonidine was found effective in reducing the
incidence of FIC (5). Dexmedetomidine (DEX),
another but more speciﬁc a-2 adrenoreceptor agonist,
may also be a useful suppressant for FIC.
We designed a double-blinded, randomized,
placebo-controlled study to test our hypothesis that
DEX decreases the incidence of FIC.
Materials and methods
Patient population
The Ethics Committee of the Second Xiangya Hos-
pital of Central South University approved this study,
and all patients gave written informed consent. The
study population consisted of 300 patients of both
genders, aged 18 to 60 years, classiﬁed as American
Society of Anesthesiologists (ASA) physical status I or
II and scheduled for elective surgery under general
anesthesia. Exclusion criteria were: body-weight more
than 20% above ideal body-weight (on the basis of
body mass index), impaired kidney or liver function,
presence of a gastric tube, a history of asthma, chronic
cough, smoking, upper respiratory tract infection
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enzyme inhibitor treatments, bronchodilators, or ster-
oids in the previous 2 weeks.
Anesthesia induction and data collection
None of the patients received any premedication.
Before being taken to the operating room, a 20-gauge
cannula was inserted into the dorsum of the patient’s
hand and connected to a T-connector for drug
administration. Upon arrival, standard ASA monitors
were attached, including non-invasive arterial pres-
sure, electrocardiography, and pulse oximetry.
Patients were randomly allocated to three groups (I,
II, III; n = 100 each) using a computer-generated table
of random numbers. All patients were given oxygen
via a face mask (2 liters per min). The patients in
group I (the control) were given 10 mL isotonic saline
intravenously (IV) over 10 min. Patients in groups II
and III received DEX 0.5 mg/kg or 1.0 mg/kg, respec-
tively, mixed with isotonic saline to a ﬁnal volume of
10 mL, over 10 min. A fentanyl bolus (4.0 mg/kg) was
then injected into all patients in less than 2 s.
Beginning immediately, an observer blinded to the
treatment group noted during the next 60 s the
incidence and severity of cough. Any episode of cough
within 60 s of fentanyl administration was classiﬁed
as FIC, and the severity was graded based on the
number of coughs (mild, 1–2; moderate, 3–4; and
severe, ‡5). Mean arterial pressure (MAP) and heart
rate (HR) were recorded immediately before injection
(T0) and every 2 min thereafter for 10 min (T1–5).
Statistical analyses
For the design of this study, an estimation of the
required minimum sample size was determined
based on a previous report of a cough incidence of
40% after an IV bolus of fentanyl (1) and an assump-
tion that a pretreatment with DEX would cause a
5 0 %r e d u c t i o ni nt h ei n c i d e n c eo fc o u g h i n g .W i t ha
probability of making a type I error (i.e. signiﬁcance
level, a) = 0.05 and the probability of making a type
II error (accepting a null hypothesis that is false,
b) = 0.20, we were required to enroll at least
91 patients in each group; we recruited 100 patients
in each group.
Data are expressed as number, proportion, percent-
age, or mean ± standard deviation. Statistical analyses
were performed using Statistical Product for Social
Sciences (SPSS) software 13.0. The frequencies of
cough and the proportions of gender and ASA class
were compared using the chi-square test or Fisher’s
exact test with Bonferroni correction. One-way anal-
ysis of variance (ANOVA) was used to compare the
ages and weights among the three groups. Repeated
ANOVA was used to compare the means of contin-
uous data of all three groups. If group differences were
found by ANOVA to be signiﬁcant, they were further
analyzed using Tukey’s Post-hoc test. A probability (P)
value < 0.05 was considered statistically signiﬁcant.
Results
Demographic characteristics
All patients completed the study. There were no
statistically signiﬁcant differences among the three
groups with regard to age, weight, gender, or ASA
class (Table I).
Incidence and severity of FIC
The incidence of FIC was 61% in group I, 40% in
group II, and 18% in group III. Groups II and III had
a signiﬁcantly lower incidence than group I (P < 0.05).
The incidence of FIC in group III was signiﬁcantly
lower than in group II (P < 0.05). However, there was
no signiﬁcant difference in the severity or onset time
of cough among the three groups (Table II).
There were also no signiﬁcant differences in
the hemodynamics data among the three groups
(Table III).
Discussion
This study demonstrated that pretreatment with
DEX, 0.5 and 1 mg/kg, reduced the incidence of
FIC from 61% (in the untreated control) to 40%
and 18%, respectively. However, the severity and
onset time of cough was unaffected, and no signiﬁcant
hemodynamic changes were observed following DEX
administration.
DEX, an a2-adrenoreceptor agonist, is widely used
in the anesthetic setting and in intensive care (6–13).
This is the ﬁrst report on the effect of DEX on FIC,
although the less speciﬁc a2-adrenoreceptor agonist
Table I. Demographics of the control (I) and treatment (II, III)
groups (n = 100, each)
a.
Demographics Group I Group II Group III
Age (y) 38.1 ± 16.6 41.2 ± 14.7 39.4 ± 17.3
Gender (M/F), n 62/38 59/41 65/35
Weight (kg) 56.4 ± 11.6 58.3 ± 10.9 55.9 ± 12.1
ASA (I/II), n 72/28 75/25 69/31
aAll patients completed the present study. There were no statisti-
cally signiﬁcant differences among the three groups with regard to
age, weight, gender, or ASA class.
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dence of FIC (5).
Many mechanisms have been proposed to explain
FIC. These include the stimulation of vagal C-ﬁber
(J or juxtacapillary) receptors, citric acid stimulating
C-ﬁbers in the airway, the release of histamine from
lung mast cells, sudden adduction of the vocal cords
or supraglottic obstruction by soft tissue, deformation
of the tracheobronchial wall stimulating irritant
receptors that lead to reﬂex bronchoconstriction
and cough, and the release of neuropeptides from
prejunctional m-opioid receptors (2,3,14–18),
Fentanyl-induced muscle rigidity is another impor-
tant causal factor. The a2-adrenoreceptor agonists’
ability to reverse opioid-induced muscular rigidity has
been demonstrated in rats (19). It is possible that a2-
adrenoreceptor agonists reduce the incidence of FIC
via reversal of fentanyl-induced muscular rigidity and
not through sedation (20). The investigation by
Horng et al. (5) demonstrated that clonidine could
suppress FIC in humans. Thus, we suggest in this
study that the effect of DEX on FIC occurs via
reversal of fentanyl-induced muscular rigidity.
Many physical methods and drugs have been
reported to prevent FIC, including propofol, lido-
caine, and ephedrine (1,3,5,14,17,21,22). All
reported methods have variable effectiveness and
potential side effects. The efﬁcacy of physical methods
for reducing FIC remains controversial. The investi-
gation by Yu et al. (4) demonstrated that dilution of
fentanyl combined with a prolonged injection time
could eliminate FIC. However, according to Schä-
permeier and Hopf’s study (23), FIC does not depend
on injection speed. A hufﬁng maneuver was reported
as a useful way to prevent FIC (24), but some patients
who receive midazolam or propofol during induction
of general anesthesia cannot use this maneuver.
Although the above-mentioned medications could
reduce the incidence of coughing, some unexpected
side-effects may occur during drug administration,
such as malignant arrhythmia, hypotension, and
hypertension. Pretreatment with lidocaine can aug-
ment the cardiovascular depression of induction
agents (25). Intravenous ephedrine before fentanyl
injection can be contraindicated in patients with cor-
onary artery disease or moderate to severe hyperten-
sion (24). Using high doses of propofol can be
associated with a high incidence of hypotension
(22). Pretreatment with clonidine is also associated
with respiratory depression, drowsiness, and severe
hypotension (5).
Pretreatment with DEX has been reported to cause
signiﬁcant hemodynamic changes (26). However, our
study demonstrates that DEX in doses of 0.5 mg/kg or
1 mg/kg can be safely used preoperatively, with stable
hemodynamics. A report of Koroglu et al.showed that
a high dose of DEX (a bolus of 2–3 mg/kg over 10 min
or infusion of 1.5–3.0 mg/kgh) in children under-
going MRI produced bradycardia in 16% of these
patients. However, the MAP and oxygen saturation
remained within normal range, and no adverse
sequelae were observed and no speciﬁc treatment
was required (13).
Table II. Incidence, severity, and onset time in seconds of fentanyl-
induced cough (FIC) in the control (I) and treatment (II, III)
groups (n = 100, each).
FIC Group I Group II Group III
Incidence (%) 61 40a 18a,b
Severity
Mild 30 19 10
Moderate 23 16 6
Severe 8 5 2
Onset (s) 23.1 ± 4.6 26.1 ± 5.0 29.2 ± 4.1
aP < 0.05, groups II and III versus group I.
bP < 0.05, group III versus group II.
Table III. Hemodynamics data of the control (I) and treatment (II, III) groups (n = 100, each)
a.
Group T0 T1 T2 T3 T4 T5
MAP (mmHg) I 86.7 ± 11.8 85.2 ± 12.1 87.2 ± 11.3 83.5 ± 11.6 86.1 ± 10.9 85.3 ± 10.7
II 83.2 ± 11.2 89.2 ± 12.3 82.1 ± 10.9 82.3 ± 10.2 80.5 ± 11.6 79.4 ± 10.1
III 85.1 ± 10.1 92.3 ± 11.8 83.4 ± 10.4 80.1 ± 9.80 78.2 ± 12.1 77.9 ± 10.5
HR (bpm) I 77.6 ± 14.5 78.2 ± 14.1 79.8 ± 12.6 76.4 ± 13.9 77.3 ± 14.7 75.1 ± 13.5
II 79.2 ± 15.0 77.5 ± 14.9 75.7 ± 13.1 73.4 ± 14.3 73.0 ± 13.8 2.6 ± 13.5
III 78.6 ± 14.1 75.3 ± 13.2 74.1 ± 13.5 72.6 ± 12.8 71.4 ± 13.6 71.2 ± 12.3
aThere were no signiﬁcant differences among the groups for either MAP or HR at any time point after DEX injection.
T0–5 = immediately before DEX injection, and at 2-min intervals, respectively, for 10 min total.
DEX = dexmedetomidine; HR = heart rate; MAP = mean arterial pressure.
20 L. He et al.A limitation of this study was that a dose-response
experiment was not performed to determine the opti-
mal dose of DEX that produces the maximum depres-
sion of FIC without causing side effects. However,
our choice of doses was based on the DEX dose used
in premedication (27). DEX is used as a premedicant
in doses of 0.5 to 1 mg/kg because of its sedative and
anesthetic-sparing effects, as well as attenuating air-
way/circulatory reﬂexes during anesthesia (11). We
chose the doses 0.5 mg/kg and 1 mg/kg and achieved
satisfactory effects, whilst maintaining hemodynamic
stability. Further studies are warranted to determine
the optimum dose of DEX that will suppress FIC
without causing side effects.
In conclusion, intravenous DEX (0.5 mg/kg or 1 mg/
kg) given immediately before the administration of IV
fentanyl (4.0 mg/kg) is a convenient way to reduce the
incidence of FIC.
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